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Craniopharyngiomas are slow growing benign tumors of the sellar and parasellar region
with an overall incidence rate of approximately 1.3 per million. During adulthood there is
a peak incidence between 40 and 44years. There are two histopathological types, the
adamantinomatous and the papillary type. The later type occurs almost exclusively in
adult patients.The presenting symptoms develop over years and display a wide spectrum
comprising visual, endocrine, hypothalamic, neurological, and neuropsychological mani-
festations. Currently, the main treatment option consists in surgical excision followed by
radiation therapy in case of residual tumor.Whether gross total or partial resection should
be preferred has to be balanced on an individual basis considering the extent of the tumor
(e.g., hypothalamic invasion). Although the overall long-term survival is good it is often
associated with substantial morbidity. Preexisting disorders are often permanent or even
exacerbated by treatment. Endocrine disturbances need careful replacement and meta-
bolic sequelae should be effectively treated. Regular follow-up by a multidisciplinary team
is a prerequisite for optimal outcome of these patients.
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INTRODUCTION
Craniopharyngiomas are rare benign tumors derived from cell
remnants of Rathke’s pouch along a line from the nasophar-
ynx to the diencephalon. The majority of these epithelial tumors
occur in the sellar, para-, and suprasellar region (Jane and Laws,
2006; Karavitaki et al., 2006; Garnett et al., 2007). In the United
States, craniopharyngiomas constitute approximately 2.5–3% of
brain tumors with an incidence rate (IR) of 1.1–1.3 per mil-
lion (Bunin et al., 1998; Jane and Laws, 2006; Karavitaki et al.,
2006). In other parts of the world, like Japan or certain parts
of Africa, IR seem to be higher (Stiller and Nectoux, 1994). A
recent analysis calculated a worldwide overall IR of 1.34 in all ages
(Nielsenetal.,2011).Abouthalf of thecasesoccurinadultswitha
peak IR between 40 and 44years according to data from a Danish
study (Nielsen et al., 2011). The male to female ratio is 1.1–1.4:1
(Nielsen et al.,2011).Although craniopharyngiomas are regarded
as benign tumors they often inﬁltrate adjacent structures like the
pituitary, hypothalamus, optic nerves, blood vessels, or the third
ventricle thereby causing signiﬁcant morbidity and mortality. As
a consequence patients present with a wide range of symptoms
which are often permanent or might even be exacerbated by
therapy. Because of their inﬁltrative growth behavior and their
high tendency for recurrence, the treatment is often challenging.
In the present article we present an overview on craniopharyn-
giomas with special emphasis on patients with adult-onset of the
disease.
PATHOLOGY AND PATHOGENESIS
Craniopharyngiomas are divided in two main histological sub-
types, the adamantinomatous and the papillary type, but transi-
tional and mixed variants have also been reported (Weiner et al.,
1994; Crotty et al., 1995; Louis et al., 2007). The adamantino-
matous type may develop at all ages, whereas the papillary type
almost exclusively occurs in adults comprising about 14–50% of
the tumors in this age group (Adamson et al., 1990; Weiner et al.,
1994; Karavitaki et al., 2006). The papillary type rarely presents
with calciﬁcations, is generally well-circumscribed and compared
to the adamantinomatous type tumor inﬁltration of surrounding
tissue is less frequent (Weiner et al., 1994; Crotty et al., 1995).
Macroscopically craniopharyngiomas are predominantly cystic or
mixed lesions although solid lesion might also occur. The tumor
size varies from small, solid, and well-circumscribed tumors to
large multilocular cysts invading the sella turcica and displac-
ing adjacent cerebral structures (Crotty et al., 1995; Karavitaki
et al., 2005). Most tumors are located in the sellar/parasellar
region with suprasellar tumor mass extension. A smaller num-
ber of tumors are conﬁned to the sella, or arise in the third
ventricle or within the optic system (Van Effenterre and Boch,
2002).
The molecular pathogenesis of craniopharyngiomas remains
widely unknown. In patients harboring the adamantinomatous
variant mutations in the beta-catenin gene CTNNB1 resulting
in degradation-resistant mutant forms of beta-catenin have been
identiﬁed (Sekine et al., 2002; Kato et al., 2004; Buslei et al.,
2005; Campanini et al., 2010). Studies in rodents showed that
permanent activation of the Wnt signaling pathway, which leads
to high expression levels of beta-catenin, causes formation of
pituitary tumors that resemble the human adamantinomatous
craniopharyngioma.Thus,reactivationof theWntsignalingpath-
waymaybeonefactorinthepathogenesisof craniopharyngiomas
of theadamantinomatoustype(Gaston-Massuetetal.,2011).The
formation of cysts and their size appears to be associated with the
expressionof carbonicanhydraseIX,anenzymecausingﬂuidpro-
duction. The speciﬁc tumor-associated regulating mechanisms,
however, of this enzyme have not been clariﬁed yet (Proescholdt
et al.,2011).
www.frontiersin.org March 2012 | Volume 3 | Article 46 | 1Zoicas and Schöﬂ Craniopharyngiomas in adults
CLINICAL MANIFESTATION
The clinical manifestations are multiple and depend on the loca-
tion of the tumor, its size, growth pattern, and relationship to
adjacent cerebral structures (Table 1).As craniopharyngiomas are
in general slowly growing, symptoms may develop gradually –
a circumstance which may contribute to the reported delay of
1–2years between symptom onset and diagnosis (Garnett et al.,
2007). In adults the most common presenting clinical symp-
toms are visual ﬁeld deﬁcits and signs of hypopituitarism (Hoff
and Patterson, 1972). In about 40–80% of the patients suprasel-
lar tumor extension pressurizes the optic chiasm causing loss of
visual acuity and visual ﬁeld abnormalities (mostly asymmetric
bitemporal hemianopsia; Crotty et al., 1995; Karavitaki et al.,
2005, 2006). In a series of 78 adult patients 57% of the female
patients reported about menstrual irregularities or amenorrhea
and 28% complained about impaired sexual function (Karavitaki
et al., 2005). Other symptoms like nausea and vomiting (26%),
poor energy (32%), and lethargy (26%) are also frequent in the
adultpatient(Karavitakietal.,2005).Thesesymptomsareindica-
tive for anterior pituitary dysfunction. Overall, growth hormone
(GH) deﬁciency is most common, followed by gonadotropin,
adrenocorticotropic hormone (ACTH), and thyroid stimulating
hormone (TSH) deﬁciency, which are present in 86, 74, 58, and
42% of adult cases, respectively (Karavitaki et al., 2005). Com-
pression of the pituitary stalk causes diabetes insipidus (DI) with
polyuria and polydipsia in 17–38.5% of cases (Karavitaki et al.,
2005; Mortini et al.,2011). Hypothalamic involvement may cause
signiﬁcant weight gain, which is a presenting symptom in 13–
15.4% of adult patients (Karavitaki et al., 2005; Mortini et al.,
2011). Severe headaches are also frequent (56%) and may be
caused by raised intracranial pressure due to the tumor mass
itself,to obstructive hydrocephalus resulting from compression of
the third ventricle or due to leaked out cyst content which could
lead to meningeal irritation (Karavitaki et al., 2006). Parasellar
tumor extension with inﬁltration of the cavernous sinus could
result in cranial nerve palsies with diplopia and paresis of ocular
muscles. Involvement of the temporal lobe might trigger seizures
and especially in the elderly, large tumors may cause deteriorat-
ing cognitive abilities and personality changes (Karavitaki et al.,
2006).
T a b l e1|P r esenting symptoms and clinical manifestations of adults with craniopharyngioma.
Cause Symptom Percentage
Compression of the pituitary
stalk or the pituitary gland
GH deﬁciency 86% (Karavitaki et al., 2005)
FSH/LH deﬁciency 74% (Karavitaki et al., 2005) to 75.6% (Mortini et al., 2011)
ACTH deﬁciency 51.3% (Mortini et al., 2011) to 58% (Karavitaki et al., 2005)
TSH deﬁciency 42% (Karavitaki et al., 2005) to 48.7% (Mortini et al., 2011)
Hyperprolactinemia 30.8% (Mortini et al., 2011) to 55% (Karavitaki et al., 2005)
Galactorrhoea 8% (Karavitaki et al., 2005)
Menstrual disorders 57% (Karavitaki et al., 2005)
Reduction or loss of sexual drive 28% (Karavitaki et al., 2005) to 42% (Crotty et al., 1995)
Cold intolerance 8% (Karavitaki et al., 2005)
Pressure on the optic nerves Visual ﬁeld defects 60% (Karavitaki et al., 2005), 80.8% (Mortini et al., 2011), 84% (Crotty et al., 1995)
Decreased visual acuity 40% (Karavitaki et al., 2005)
Optic atrophy 14% (Karavitaki et al., 2005)
Blindness 3% (Karavitaki et al., 2005)
Hypothalamic involvement Weight gain/hyperphagia 13% (Karavitaki et al., 2005) to 15.4% (Mortini et al., 2011)
Diabetes insipidus 17% (Karavitaki et al., 2005) to 38.5% (Mortini et al., 2011)
Polyuria/polydipsia 15% (Karavitaki et al., 2005) to 27% (Crotty et al., 1995)
Other causes Personality changes 8% (Karavitaki et al., 2005)
Headache 56% (Karavitaki et al., 2005) to 68% (Crotty et al., 1995)
Somnolence 10% (Karavitaki et al., 2005)
Nausea and vomiting 26% (Karavitaki et al., 2005)
Loss of energy 32% (Karavitaki et al., 2005) to 48% (Crotty et al., 1995)
Lethargy 26% (Karavitaki et al., 2005)
Other cranial nerves palsies 9% (Karavitaki et al., 2005)
Papilledema 6% (Karavitaki et al., 2005)
Cognitive impairment 17% (Karavitaki et al., 2005) to 22% (Crotty et al., 1995)
Anorexia/weight loss 8% (Karavitaki et al., 2005)
Decreased consciousness/coma 4% (Karavitaki et al., 2005)
Unsteadiness/ataxia 3% (Karavitaki et al., 2005)
Hemiparesis 1% (Karavitaki et al., 2005)
Meningitis 3% (Karavitaki et al., 2005)
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DIAGNOSIS
The suspicion of a craniopharyngioma is based on clinical and
radiological ﬁndings. The diagnosis is ﬁnally proven by histology.
Aproposalfortheinitialdiagnosticwork-upinpatientssuspicious
for craniopharyngioma is given in Table 2.
Most adult patients present with visual ﬁeld deﬁcits and signs
of hypopituitarism (Hoff and Patterson, 1972). Visual ﬁeld and
visual acuity assessment is therefore important to determine any
deﬁcit and to establish baseline values. In addition, an examina-
tion of the optic disks is required to rule out papilledema and
visual evoked potentials are recommended. An endocrine eval-
uation should include the assessment of anterior and posterior
pituitary functions. Signs and symptoms indicative for hypopitu-
itarismincludingDIshouldbeaskedfor.BasalACTHandcortisol,
TSH and free T4,LH and testosterone in men and FSH and estra-
diol in women, IGF-1 and prolactin as well as serum electrolytes,
serum, and urine osmolality are determined. Further endocrine
testings should be performed according to the results and the
individual clinical situation.
Cranial computer tomography (CT) and/or magnetic reso-
nanceimaging(MRI)withandwithoutcontrastenhancementare
part of the neuroradiological evaluation of craniopharyngiomas.
Calciﬁcations and bony structures are best evaluated on CT,while
the delineation of tumor size and the involvement of neighbor-
ing structures can be assessed most accurately by MRI. The MRI
scan is therefore the method of choice in order to prepare a sur-
gical approach (Garnett et al., 2007). According to a recent study,
there are no signiﬁcant differences in neuroradiological charac-
teristics of craniopharyngiomas between children and adults with
theexceptionof lowerratesof tumorcalciﬁcationinadultpatients
(Mortini et al., 2011). In some studies hydrocephalus occurred
less frequently in adults than in children, however other authors
reported no differences in this regard (Van Effenterre and Boch,
Table 2 | Diagnostic work-up of patients with craniopharyngioma.
Anamnesis Visual ﬁeld deﬁcits, loss of visual acuity?
Loss of libido, amenorrhea?
Polyuria, polydipsia?
Headaches?
Nausea, vomiting?
Weight gain?
Fatigue, tiredness
Sleep disorders?
Concentration deﬁcits?
Cold intolerance?
Neuroimaging MRI
CT
Laboratory tests IGF-1, prolactin, ACTH, cortisol, TSH, fT4,
LH, FSH, testosterone ( )/estradiol ( ) serum
electrolytes, serum-osmolality, urine
osmolality
Ophthalmological evaluation Visual acuity testing
Visual ﬁeld perimetry
Optic disks evaluation (visual evoked
potentials)
2002;Karavitakietal.,2005).Althoughseveralattemptshavebeen
made,noreliablediscriminationbetweenthetwohistologicalsub-
types is possible based on neuroradiological criteria (Crotty et al.,
1995; Eldevik et al., 1996; Sartoretti-Schefer et al., 1997). In some
cases the presence of a craniopharyngioma is suggested by an
incidental ﬁnding of a mass lesion on neuroimaging scans. The
differentialdiagnosiscomprisesothersellarandparasellartumors
like Rathke’s cleft cysts and other non-malignant cysts, pitu-
itary adenomas, optic and hypothalamic gliomas, meningiomas,
teratomas, germinomas, lymphomas, metastases, and inﬁltrative
diseases, like sarcoidosis or systemic histiocytosis (Garnett et al.,
2007).
TREATMENT
Prospective and controlled studies comparing different treatment
strategiesinadultpatientsaremissing.Mostdatacomefromretro-
spectiveanalysesofmixedpopulationsofpatientswithchildhood-
and adult-onset disease. There are no evidence-based guidelines
or a clear consensus for best treatment of primary or recur-
rent craniopharyngiomas in adults. Like in children a radical
approachwithcompletetumorresectionandpotentialcurehasto
be balanced with a more conservative approach to avoid substan-
tialtreatment-associatedlong-termmorbidity.Therefore,optimal
treatment should always be individualized taking into account,
e.g., the patient’s symptoms, age, tumor localization, and exten-
sion. Endocrine and metabolic complications should be treated
prior to any tumor-directed therapy such as surgery. This is espe-
cially important in case of adrenal or thyroidal insufﬁciency, as
well as DI. It is generally agreed that a multidisciplinary team
comprisingendocrinologists,neurosurgeons,radiotherapists,and
ophthalmologists is essential for optimized treatment of patients
of any age (Garnett et al., 2007; Garre and Cama, 2007; Honegger
and Tatagiba, 2008).
SURGERY
Surgeryistheﬁrst-lineapproachtothetreatmentofcraniopharyn-
giomas. Complete surgical resection is the goal of initial therapy
and because of major advances in neurosurgical techniques, it is
increasingly feasible. However, due to their size, their often irreg-
ular margins and intense peritumoral gliosis with adherence to
vital neighboring neurovascular structures this is often difﬁcult
and potentially dangerous. According to the literature complete
tumor removal by radical surgery can be achieved in 18–84% of
selected childhood and adult cases (Weiner et al.,1994; Fahlbusch
et al.,1999;Van Effenterre and Boch,2002; Karavitaki et al.,2005,
2006). Aggressive surgery with gross total resection (GTR) of the
tumor,however,mayresultinsigniﬁcantanddevastatingperi-and
postoperativemorbidityespeciallyafterresectionoftumorsinvad-
ing the hypothalamus (Rutka, 2002). If complete tumor removal
is unlikely to be achieved or too hazardous, subtotal, or partial
resection (PR) of the tumor, e.g., to reduce pressure effects on
adjacent structures like the optic pathways and/or to re-establish
circulation of the cerebrospinal ﬂuid with or without subsequent
radiotherapy is an alternative approach (Habrand et al., 1999;
Cama et al., 2006). In any case the beneﬁts of surgery must be
balanced against the risks of treatment-related morbidity. For
pediatricpatientsapreoperativegradingsystemhasbeenproposed
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accordingtothedegreeof hypothalamicinvolvement(Pugetetal.,
2007). Using this classiﬁcation a signiﬁcant relationship between
the preoperative tumor grade and post-surgical morbidity could
be demonstrated. GTR should only be attempted in patients
without hypothalamic involvement (grade 0) or with a distorted
or elevated but still visible hypothalamus (grade 1). In grade 2
craniopharyngiomas (hypothalamic structures not discernible) a
subtotal resection leaving the hypothalamic part is recommended
(Puget et al., 2007). Similar studies in adults are lacking. Nev-
ertheless it appears reasonable to follow these recommendations
established in pediatric patients. For craniopharyngiomas with
major cystic portions stereotactic cyst decompression is another
treatmentoption.Thiscanbeusedforacutesymptomatictherapy,
prior to deﬁnite craniopharyngioma resection, or may be recom-
mended as intermittent therapy whenever a total cyst excision
is not possible (Fahlbusch et al., 1999; Honegger and Tatagiba,
2008).
RADIOTHERAPY
Radiotherapy (RT) is a therapeutic option in patients for whom
surgeryiscontraindicated,withresidualtumortissueaftersubtotal
or partial surgical resection, as well as in patients with recur-
rent disease. Advances in RT techniques allow higher treatment
precision with less long-term toxicity by focusing the ionizing
radiation on the tumor and limiting the exposure of adjacent
tissues to a minimum. Techniques used for the treatment of cran-
iopharyngiomas include stereotactic fractionated radiotherapy,
radiosurgery, intensity modulated radiation therapy, and proton
beam therapy (Fitzek et al., 2006; Minniti et al., 2009; Niran-
jan et al., 2010). For fractionated conformal RT schedules the
probability of local tumor control is best with radiation doses
above 54–55Gy (Regine et al., 1993) but less than 61Gy to
lower the risk of radiation-associated side-effects such as visual
impairment, pituitary deﬁciency, impaired cognitive function or
development of secondary malignancies (Cavazzuti et al., 1983;
Merchant et al., 2006). Application of radiosurgery with deliv-
ery of a single high-dose radiation to the tumor is an attractive
technique but restricted to smaller tumor volumes and requires
sufﬁcient safety margins of adjacent critical structures. Although
reports published so far are promising (Minniti et al., 2009;
Iwata et al., 2012), further studies are needed to deﬁne its role
in the prevention of tumor recurrence and its potential long-
term adverse effects. Intracavitary irradiation with stereotactically
guided instillation of radioisotopes is another approach to treat
mono- or multicystic tumors (Voges et al., 1997; Barriger et al.,
2011).
OTHER TREATMENTS
Other treatment options for predominantly cystic craniopharyn-
giomas comprise intracystic chemotherapy or immunological
therapy with bleomycin or interferon alpha, respectively (Stein-
bok and Hukin, 2010). The experience regarding these treat-
ments is mainly restricted to pediatric patients. In general, these
options were used for temporary tumor control with the expec-
tation for further therapies like surgery or radiotherapy. Systemic
chemotherapyisgenerallyregardedasineffective(Karavitakietal.,
2006).
RECURRENT DISEASE
Recurrence of craniopharyngiomas remains a problem which
highly impacts on the long-term prognosis of the patients. In a
recent study with 106 patients including 78 adults, 24.5% experi-
enced a relapse within a median follow-up of 83months (Mortini
et al., 2011). The risk of recurrence appears highest in the ﬁrst
3years after surgery and then tends to reach a plateau (Fahlbusch
et al., 1999; Karavitaki et al., 2005). After GTR the risk of tumor
recurrence has been reported to range between 0 and 26% (Maira
et al., 1995; Fahlbusch et al., 1999; Duff et al., 2000). This is sig-
niﬁcantly lower than in patients with subtotal or partial tumor
resection in whom tumor recurrence occurs in 25–100% of the
patients (Fahlbusch et al.,1999; Duff et al.,2000; Karavitaki et al.,
2005). In these patients adjuvant RT signiﬁcantly improves the
tumor control rates with recurrence rates ranging from 10 to 63%
at 10-years follow-up (Karavitaki et al.,2006). Thus,patients with
subtotal resection without subsequent RT have the highest risk of
relapse(Duffetal.,2000;Karavitakietal.,2005).Inpatientstreated
withRTalonetumorgrowthorrecurrencewasobservedin0–23%
of thepatientsat10yearsfollow-up(Hetelekidisetal.,1993;Rajan
et al., 1993). The data about the prognostic signiﬁcance of age at
diagnosis, gender, tumor size, location, or consistency, as well as
the histological subtype are inconsistent (Karavitaki et al., 2005,
2006;Mortinietal.,2011),butingeneralthesefactorsdonotseem
to affect the risk of recurrence (Karavitaki et al.,2006).
TREATMENT OF RECURRENT DISEASE
Recurrent disease is difﬁcult to treat. Because of scars and adhe-
sions due to previous surgery or radiation, the surgical success
rates for recurrent disease are signiﬁcantly lower than for primary
surgeryandperi-andpostoperativemorbidityandmortalityissig-
niﬁcantly increased (Yasargil et al., 1990; Wisoff, 1994; Fahlbusch
et al., 1999; Karavitaki et al., 2005). Therefore, the severity of
clinicalsymptomshastobetakenintoaccountandithasbeensug-
gestedthatrepeatedsurgeryshouldonlybeperformedwhenacute
pressure effects occur (Karavitaki et al.,2006). In patients not pre-
viouslytreatedwithRTirradiationisanotheroptioneitherinstead
of or following a second surgery, and it appears that RT is equally
effective in the control of recurrent tumors as for primary treat-
ment (Jose et al.,1992). Further options comprise cyst controlling
procedureslikeaspiration,intracysticirradiationorapplicationof
bleomycin,salvage surgery in case of life-threatening solid lesions,
or radiosurgery. In any case treatment decisions for recurrent
disease should be made on an individualized basis.
DISEASE AND TREATMENT COMPLICATIONS
ENDOCRINE
Anterior pituitary dysfunction and DI are common in adult
patientswithcraniopharyngiomasandthemajorityof adultcran-
iopharyngioma patients present with signs and symptoms of
hypopituitarism (Paja et al., 1995; Honegger et al., 1999; Karavi-
taki et al., 2005). Neuroendocrine dysfunction may worsen upon
treatment. In a recent study by Mortini et al. (2011) 82.3, 75.9,
72.7, and 66.7% of patients with normal baseline values for GH,
ACTH, TSH, and gonadotropins developed a new deﬁciency of
the respective pituitary axis after surgery. Post-surgical onset of
DI was observed in 69.6% of their patients. The risk for new
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hormone deﬁciencies appears to be lower after transsphenoidal
operation (Honegger et al.,1999; Mortini et al.,2011). In contrast
to pituitary adenomas, recovery of preexisting pituitary dysfunc-
tion after surgery is rare (Webb et al., 1999; Mortini et al., 2011).
Although symptomatic DI appears to occur more frequent in sur-
gically treated patients (Hetelekidis et al., 1993; Karavitaki et al.,
2006), long-term endocrine morbidity in general seems not to be
affected by the type of therapy (Weiner et al.,1994;Habrand et al.,
1999;Karavitaki et al.,2005). Most of the patients chronically suf-
fer from partial or complete hypopituitarism as well as DI, with
approximately 80% requiring the substitution of more than two
hormones (Kendall-Taylor et al.,2005;Verhelst et al.,2005). Con-
cerning GH substitution, observational studies suggest that GH
replacement does not increase the risk of tumor recurrence (Abs
et al., 1999). Because of the often complex endocrine morbidity
lifelong surveillance by an endocrinologist is required.
VISUAL
In adults impaired visual function is common at ﬁrst presentation
(Crotty et al., 1995; Karavitaki et al., 2005, 2006). After surgical
decompression visual deﬁcits often improve,but may also remain
unchanged or even become worse (Fahlbusch et al., 1999; Van
Effenterre and Boch, 2002; Mortini et al., 2011). In a series of 173
patients treated with RT only or after limited surgery, improve-
ment in visual ﬁeld defects or in visual acuity was observed in 36
and 30%,respectively after a median follow-up of 12years (Rajan
etal.,1993).Inaboutone-thirdof thepatientspretreatmentvisual
deﬁcits deteriorated (Rajan et al., 1993). No radiation optic neu-
ropathy developed by applying accurate RT techniques and doses
below the tolerance limit of the optic system (Harris and Lev-
ene, 1976; Rajan et al., 1993). Karavitaki et al. (2005) reported
in their series of patients with long-term follow-up about major
visual ﬁeld defects in 49 and 72% of the patients after 10 and
20years,respectively.Thisreﬂectstreatment-associateddeteriora-
tion of visual function on the one hand and on the other hand the
natural course of the disease with a high risk for recurrence. Risk
factorsforadversevisualoutcomearethepresenceof visualsymp-
toms at diagnosis, irradiation dose above 2Gy per day, and a PR
of the tumor,probably because of the increased risk of recurrence
(HarrisandLevene,1976;Karavitakietal.,2005,2006).Long-term
follow-up by an ophthalmologist is recommended.
HYPOTHALAMIC AND METABOLIC
Tumor- or treatment-related damage of the ventromedial hypo-
thalamus may lead to the impairment of mechanisms control-
ling satiety, hunger, and energy expenditure resulting in severe
obesity (Daousi et al., 2005). Hypothalamic obesity is the most
common manifestation of hypothalamic complications. At pre-
sentation about 15% of adult patients complain about excessive
weight gain or are obese (Karavitaki et al., 2005; Mortini et al.,
2011).Duringlong-timefollow-upexcessiveweightgainhasbeen
reported in up to 67% of patients after surgery with and with-
out adjuvant RT (Hoffman et al., 1992; Karavitaki et al., 2005).
Hypothalamic obesity is often associated with disastrous meta-
bolic and psychological consequences leading to severe morbidity,
impaired quality of life, and reduced life expectancy (Karavitaki
et al., 2006). Features of the metabolic syndrome like abdominal
obesity, dyslipidemia, hyperinsulinemia caused by insulin resis-
tance,and elevated blood pressure are commonly seen in patients
with craniopharyngiomas (Kendall-Taylor et al., 2005; Pereira
etal.,2005;Holmeretal.,2009).Inaretrospectiveanalysisfromthe
KIMSdatabasepatientswithadult-onsetdiseaseweremoreobese,
had a greater waist circumference, and had higher cholesterol
and triglycerides levels with similar HDL- and LDL-cholesterol
whencomparedtopatientswithchildhooddiseaseonset(Kendall-
Taylor et al., 2005). Together, these metabolic alterations increase
the risk of hypertension, diabetes, and atherosclerosis, which all
lead to cardiovascular disease and mortality from vascular events
(Van Gaal et al., 2006). Thus, the necessity for treatment is vital
but treatment of hypothalamic obesity is difﬁcult and patients
need to comply with dietary and behavioral modiﬁcations com-
prising regular physical activities, require anti obesity drugs, or
even bariatric surgery (Karavitaki et al., 2006). DI with an absent
sense of thirst is another hypothalamic complication resulting in
serious water and electrolyte imbalances, which was observed in
19% of adult patients after surgery with and without adjuvant
RT (Smith et al., 2004). Sleep disorders and increased daytime
somnolence caused by disruption of the circadian rhythm occur
in up to one-third of adult craniopharyngioma patients (van der
Klaauw et al., 2008). Impaired thermoregulation with hyper- or
hypothermia has also been observed in adults (Lipton et al.,1981;
Grifﬁthsetal.,1988).Riskfactorsforhypothalamiccomplications
are preexisting disorders at diagnosis, young age at presentation
of symptoms, hypothalamic invasion, tumor size, multiple oper-
ations due to recurrence, and hypothalamic radiation with doses
a b o v e5 1G y( de Vile et al., 1996; Lustig et al., 2003; Poretti et al.,
2004).
NEUROPSYCHOLOGICAL AND COGNITIVE DYSFUNCTION
Behavioral problems and deteriorated cognitive functions are rel-
atively common, which contribute to decreased academic and
occupational performance, difﬁculties in maintaining family, and
social relationships, resulting in a loss in quality of life (Cavazzuti
et al.,1983; Karavitaki et al.,2006).
OTHERS
In patients who received RT vascular damage like aneurysms and
secondary brain tumors may occur (Enchev et al.,2009; Liu et al.,
2009).
LONG-TERM PROGNOSIS AND MORTALITY
Control of tumor growth and the disease- or treatment-related
complications determine the long-term prognosis. Overall sur-
vival rates reported range from 89 to 94% at 5-years and from 85
to90%at10-yearsfollow-up(VanEffenterreandBoch,2002;Kar-
avitaki et al., 2005). Nevertheless, overall mortality appears three
to ﬁve times higher than those of the general population (Sher-
locketal.,2010).Currently,itisunclearwhichtherapeuticstrategy
(e.g., GTR or subtotal or PR followed by radiotherapy) is associ-
ated with a better survival (Karavitaki et al., 2005; Sherlock et al.,
2010)andwhetherthehistologicalsubtypeisof relevance(Weiner
et al.,1994). Recurrent disease,however,is signiﬁcantly associated
with increased morbidity and mortality, resulting in lower 10-
year survival rates (29–70%; Karavitaki et al.,2005; Honegger and
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Tatagiba, 2008). Apart from mortality caused by the tumor itself
or by surgical treatment, mortality from cardio- and cerebrovas-
cular as well as respiratory causes is increased (Bulow et al., 1998;
Tomlinson et al., 2001). It is therefore essential to optimize the
treatment of any endocrine and metabolic sequelae of the disease
in order to reduce mortality in this high risk patient population.
CONCLUSION
Although craniopharyngiomas are generally benign their loca-
tion, size, and tendency to inﬁltrate adjacent cerebral structures
makestheirmanagementratherdemandingandmayleadtosome-
times devastating complications. According to the data available
adult-andchildhood-onsetcraniopharyngiomasbehavesimilarin
many aspects. Treatment decisions for primary or recurrent dis-
ease need to consider long-term tumor control as well as disease
and treatment-related morbidity and they are often reached on
an individualized basis. Surgery is the initial treatment approach,
which should remove as much tumor as safely possible, while
avoiding severe treatment-induced complications. There is some
controversy as to whether a more radical surgical approach with
gross total tumor resection should be aimed at or a more limited
approach with reducing the tumor mass followed by radiother-
apy in order to minimize long-term morbidity. As some patients
with subtotal or partial tumor resection may have stable disease
and since RT may cause long-term complications it is currently
unclear, whether all patients with residual tumor should receive
immediate postoperative RT. Likewise it is unknown which ther-
apeutic strategy is best in patients with tumor recurrence despite
RT. Posttreatment follow-up should include neuroimaging with
MRI, visual assessment, and monitoring of endocrine functions
and metabolic status. Endocrine and metabolic alterations need
tobetreatedadequately.Thereisnodoubtthatforoptimalresults
a lifelong surveillance of an experienced multidisciplinary team is
essential.
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